Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.44
- Piotroski Score 3.00
- Grade Neutral
- Symbol (AADI)
- Company Aadi Bioscience, Inc.
- Price $2.31
- Changes Percentage (1.32%)
- Change $0.03
- Day Low $2.25
- Day High $2.33
- Year High $5.70
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $1.63
- High Stock Price Target $1.75
- Low Stock Price Target $1.50
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.55
- Trailing P/E Ratio -0.68
- Forward P/E Ratio -0.68
- P/E Growth -0.68
- Net Income $-65,765,000
Income Statement
Quarterly
Annual
Latest News of AADI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Aadi Bioscience to Halt Tumor Treatment Trial, Preserve Cash Flow With Job Cuts
Aadi Bioscience will stop a tumor treatment trial due to lack of efficacy. The company will now focus on conserving cash by pausing other trials and reducing its research staff by 80%, aiming to prolo...
By MarketWatch | 3 months ago -
We're Keeping An Eye On Aadi Bioscience's (NASDAQ:AADI) Cash Burn Rate
Investors are attracted to unprofitable companies like Aadi Bioscience due to growth potential. However, increasing cash burn and funding difficulties raise concerns. Analyst forecasts and risks shoul...
By Yahoo! Finance | 3 months ago
